Navigation Links
Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
Date:2/8/2008

SALT LAKE CITY, Feb. 8 /PRNewswire/ -- Alynx, Co. (OTC Bulletin Board: AYXC) announced today it has completed its acquisition of 100% of the outstanding shares of MiMedx, Inc., a development-stage medical device company, based in Tampa, Florida.

In connection with the transaction, structured as a reverse merger, Alynx issued approximately 52.9 million new shares of its common stock, and approximately 3.7 million new shares of its preferred stock (convertible into approximately 56.9 million shares of its common stock, subject to specified conditions). Also in connection with the merger, Alynx repurchased and canceled 20.0 million shares of its outstanding common stock. After the merger, there is a total of approximately 55.8 million shares of common stock and 3.7 million shares of preferred stock of Alynx outstanding, with former MiMedx shareholders holding approximately 97.25% on a fully-diluted basis. The shares issued in the merger were issued pursuant to a private placement and are not presently eligible for resale to the public.

The executive officers and directors of MiMedx became the executive officers and directors of Alynx after the merger. The board of Alynx has expressed its intention to call a meeting of shareholders in the near future. One of the purposes of the meeting would include a proposal to approve a reverse stock split of approximately one-for-three for each share of Alynx common stock, reducing the total shares outstanding to approximately 36.5 million shares. If the board calls a meeting of shareholders, appropriate filings would be made with the SEC and proxy materials would be provided to Alynx shareholders, who would then have the opportunity to consider and vote upon the proposal. There can be no assurance that the proposal will be submitted, and if submitted, the proposal may vary from the proposals presently contemplated. Furthermore, there can be no assurance the proposal will be approved by the shareholders.


'/>"/>

SOURCE MiMedx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Carrington Completes $8 Million Financing
5. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
6. New Brunswick Scientific Completes Merger Transaction with Eppendorf
7. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Optherion, Inc. Completes $37 Million Start Up Financing
10. Companys Partner Completes Trial Production of a New Antiviral Medicine
11. American Oriental Bioengineering Completes Acquisition of Guangxi Boke Pharmaceutical Company Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- , - Results From a ... Arthritis in Seven Major Industrialized Countries , , ... say their disease, impacts their ... living with rheumatoid arthritis find shopping for gifts, ... presents most, difficult to do, ...
(Date:12/11/2009)... (Nasdaq: DNDN ) announced today that the ... exercised in full their option to purchase an ... public offering price of $24.75 per share. ... of the offering to an aggregate of 17,250,000 ... receive net proceeds from the offering of approximately ...
(Date:12/11/2009)... a new explanation for differences in the severity of mental ... gene, the more serious the handicap. The genetic defect is ... is the amount of copies of the GDI1 gene that ... American Journal of Human Genetics , and are the result ... VIB, a life sciences research institute in Flanders, Belgium at ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment and dosing ... Center of the first patient in the ACE ( ... fficacy) Phase 2 pivotal trial in patients with relapsed ... a novel, orally available, potent and highly selective small ... kinase-3 (FLT3) inhibitor. The ACE study is designed ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5
... be held October 29-31 at the Palace Hotel, ... Lehrman Group, the world,s,marketplace for expertise, and the ... for the Seventh Annual BIO Investor,Forum. Featured therapeutic ... physician consultants along with executives from public and,private ...
... 24 Researchers at 28th annual,National Academy ... City this,weekend will present data to help ... breast cancer survivors affected by,"Chemobrain". Chemobrain is ... types of cancer. It is associated with ...
... Oct. 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ... and medical device company, today announced that its ... place on October,30, 2008 at 8:30am Pacific time ... To listen to the meeting, please dial ...
Other Biology Technology:Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 2Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 3Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain' 2
(Date:12/11/2009)... to identify and degrade the diverse types of defective ... The researchers Sabine C. Horn, Professor Thomas Sommer, Professor ... Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have ... an enzyme complex that plays a critical role in ... regulating the identification and disposal of various defectively produced ...
(Date:12/11/2009)... available in French . , Montreal, ... novel molecular mechanism that prevents cancer. In the December ... , scientists from the Universit de Montral and the ... SOCS1 molecule prevents the cancer-causing activity of cytokines, hormones ... as Crohns, in smokers and people exposed to asbestos. ...
(Date:12/11/2009)... 2009 Keystone Symposia on Molecular and Cellular ... five new Keystone Symposia Fellows for 2010. Launched ... early-career life scientists (postdoctoral trainees or assistant professors) ... for one year. Fellows are selected based on ... to promoting diversity in the biomedical and life ...
Breaking Biology News(10 mins):MDC researchers identify a scaffold regulating protein disposal 2Scientists identify natural anti-cancer defenses 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers 59835 1Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers 59835 2Happy flies look for a place like home 10440 1Happy flies look for a place like home 10440 2Researchers find ways to encourage spinal cord regeneration after injury 10437 1Researchers find ways to encourage spinal cord regeneration after injury 10437 2
... only catch fleeting glimpses of it. Up until recently, ... marine biologists and ecologists, but advances in electronic tracking ... deeper under, the surface of the oceans than ever ... giving researchers insights into the behavior and lifestyles of ...
... French . , Imagine a gigantic, inflatable, sausage-like bag ... the equivalent of 2.2 days of current global emissions. ... metres in radius and several kilometres long, resting benignly on ... , At first blush, this might appear like science fiction, ...
... Women,s & Children,s Hospital and the University of Adelaide, ... infection with high blood pressure during pregnancy and pre-term ... Journal of Obstetrics & Gynaecology, are a major step ... high blood pressure in pregnancy. , The research has ...
Other Biology News:Unveiling the underwater ways of the white shark 2Unveiling the underwater ways of the white shark 3Into the abyss: Deep-sixing carbon 2Herpes virus link to complications in pregnancy 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Inquire...
1M stock solution (238mg/ml)...
...
Biology Products: